Written by ι Stock Market Media Group Staff — May 28, 2013
Plandaí Biotechnology, Inc.’s (OTCQB: PLPL) Phytofare™ brand will feature three botanical extracts with a much higher bioavailability than the current market offers. In a three-part series covering each of the new products, Stock Market Media Group, formerly Stock House Group, a full service research and content development investor relations firm, has covered the green tea based Phytofare™ Catechin Extract and the company’s citrus based Phytofare™ Limonoid Glycoside Complex. In this third installment, Plandaí’s tomato based Phytofare™ Carotenoid Extract will be highlighted.
Each of the three new products will be individually labeled and branded under the Phytofare™ name and these products will offer a much higher absorption rate to the company’s customers. Phytofare™ Carotenoid Extract is produced from tomato and formulated in oleoresin containing lycopene and the opaque precursors phytoene and phytofluene in a highly concentrated, pure, stable and bioavailable form.
There have been more than 250 scientific studies conducted in the last 15 years and those studies have shown that carotenoids like lycopene have important health benefits for cardiovascular disease and certain cancers. The best results have been seen with breast, skin, prostate and colon cancers.
Prostate cancer, in particular, has received considerable attention with protective effects reported 19 times and one study that highlighted the benefit of processed tomato products over fresh tomatoes. The biggest limitation of using lycopene as a nutraceutical has been the poor bioavailability, stability, and rapid degradation to heat and light. Plandaí Biotechnology’s proprietary technology will change that since, with its hydrodynamic sheering process, live plant-materials are converted at the molecular level during extraction into a nano-particle sized isomeric structure that resembles that found in human tissues.
Plandaí’s extraction process has been shown to increase the bioavailability of phytonutrients and antioxidants by decreasing the size of the molecule and then changing the properties of the molecules so that they mimic that of human tissues. The smaller the size, the more easily it can pass through cell walls. Plandaí’s CEO Roger Duffield said of the technology:
“A high percentage of drug compounds are synthesized analogs of plant molecules. While botanical material can have tremendous curative properties, it generally has poor bioavailability—or low absorption in human tissues. This is because human tissues have a different molecular structure than plant matter. A synthetic drug tries to recreate the beneficial elements using a molecule that has greater bioavailability. Unfortunately, these synthetics often have adverse side effects and, over time, can result in drug-resistant strains of the disease.
Our patented technology allows us to take specific types of live plant material and unzip the molecules, releasing all of the phytonutrients, and then rearrange the isomeric configuration of the molecule so that it mimics the 50/50 ratio commonly found in human tissues. Simultaneously, we’re able to take out any undesirable elements and reduce the particles to mostly nano-size.
What this means is that we are able to tailor design the living molecule to maximize the phytonutrient properties and absorption. So, where most phytonutrients are poorly absorbed in humans, often less than 10%, our products are more fully absorbed.”
The CEO says the company is able to do this because it’s using live plant materials. From the moment of harvest, Plandaí maintains the material at an optimal temperature and then they begin the extraction process within the hour. This allows the company to ensures that they are releasing and capturing live anti-oxidants, resulting in a product that is 100% pure bioactive.
Duffield added, “We believe that this technology is the foundation for creating a whole new family of drugs that can treat a multitude of diseases and conditions, safely and affordably using naturally-derived extracts.”
Lycopene is currently formulated as a dietary supplement in various dosages or as a food ingredient and the market is currently dominated by the manufacturer Lyc-O-Red. Formulated in oleoresin or beads, the Lyc-O-Mato™ extract consists of 95% trans isomers, and only 1% released phytoene and phytofluene with acknowledged poor bioavailability and shelf life. Phytoene and Phytofluene are immature opaque lycopene isomers and are formulated into skin care products.
Phytofare™ Carotenoid Extract on the other hand, is a natural botanical extract providing the body’s capillaries and immune system with biological chemo-preventive and antioxidant activities relating to anti-aging, cardiovascular diseases, cancers and cholesterol lowering benefits.
In 2012, the scientific journal, Food Chemistry, which publishes original research papers dealing with the chemistry and biochemistry of foods and raw materials, published the work done in USDA investigations with Phytofare™ tomato emulsions and powders. The tomato emulsions and powders were compared for lycopene, phytoene, and phytofluene contents. In the investigations, the USDA found extractable lycopene, phytoene and phytofluene increased significantly by more than 50%. In the published investigation, Dr. Ishida stated:
“In nature, lycopene exists almost exclusively as the all-trans stereoisomer. Cis-lycopene isomers form during cooking and digestion, resulting in higher percentages in plasma and tissues than ingested. Cis-lycopene isomers are more bioavailable than all-trans lycopene. Extraction using this proprietary method increased extracted cis-lycopene to as high as 43% of the total lycopene, indicating increased isomerization. The process therefore will contribute significantly to the delivery of health benefits of biologically available lycopene from tomato products for metabolic functions.”
Phytofare™ Carotenoid Botanical Extract has pharmaceutical-grade purity and is more bioavailable and stable than competing extracts. And, like the company’s other two products, documented research shows Phytofare™ is clinically proven to have far superior absorption. The higher bioavailability in each of the company’s products translates into the ability for users to receive a clinical dose with lower quantities.